 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 December 1996 | Volume 125 Issue 12 | Pages 969-974
Background: It is often difficult to administer extended antibiotic therapy in the hospital for right-sided Staphylococcus aureus endocarditis. Although the effectiveness of single-drug therapy given for 4 to 6 weeks and that of two-drug therapy given for 2 weeks have been shown, no data are available on the effectiveness of short-course single-drug therapy.
Objective: To compare the efficacy of cloxacillin alone with that of cloxacillin plus gentamicin for the 2-week treatment of right-sided S. aureus endocarditis in intravenous drug users.
Design: Open, randomized study.
Setting: An academic tertiary care hospital in Barcelona, Spain.
Patients: 90 consecutive intravenous drug users who had isolated tricuspid valve endocarditis caused by methicillin-susceptible S. aureus, had no allergy to study medications, and had no systemic infectious complications that required prolonged therapy. An efficacy subset consisted of 74 of these patients who did not meet an exclusion criterion.
Intervention: Cloxacillin (2 g intravenously every 4 hours for 14 days) alone or combined with gentamicin (1 mg/kg of body weight intravenously every 8 hours for 7 days).
Measurements: Clinical or microbiological evidence of active infection after 2 weeks of therapy, relapse of staphylococcal infection, or death.
Results: In an analysis of the efficacy subset, treatment was successful in 34 of the 38 patients who received cloxacillin alone (89% [95% CI, 75% to 97%]) and 31 of the 36 patients who received cloxacillin plus gentamicin (86% [CI, 71% to 95%]). Three patients died: one in the cloxacillin group and two in the combination therapy group. Of the 37 patients who completed 2-week treatment with cloxacillin, 34 (92%) were cured, and 3 (8%) needed prolonged treatment to cure the infection. Of the 34 patients who completed 2-week treatment with cloxacillin plus gentamicin, 32 (94%) were cured and 2 (6%) required treatment for 4 weeks. One patient in the combination group had relapse.
Conclusions: A penicillinase-resistant penicillin used as single-agent therapy for 2 weeks was effective for most patients with isolated tricuspid endocarditis caused by methicillin-susceptible S. aureus. Adding gentamicin did not appear to provide any therapeutic advantages. Additional studies to confirm the therapeutic equivalence of short-course therapy with penicillinase-resistant penicillin alone and therapy with combined regimens are warranted.
Author and Article Information
From Hospital Vall d'Hebron, Universidad Autonoma, Barcelona, Spain.
ARTICLE
Effectiveness of Cloxacillin with and without Gentamicin in Short-Term Therapy for Right-Sided Staphylococcus aureus Endocarditis
A Randomized, Controlled Trial
Acknowledgments: The authors thank Walter R. Wilson of the Mayo Clinic for his critical review of the manuscript and Celine Cavallo for her assistance with the English language.
Requests for Reprints: Esteban Ribera, MD, Hospital General Vall d'Hebron, Universidad Autonoma, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Current Author Addresses: Drs. Ribera, Gomez-Jimenez, Cortes, Almirante, Ocana, and Pahissa: Servicio de Enfermedades Infecciosas, Hospital General Vall d'Hebron, Universidad Autonoma, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain.
This article has been cited by other articles:
|
|
 |
|
  D. Yung, D. Kottachchi, B. Neupane, S. Haider, and M. Loeb Antimicrobials for right-sided endocarditis in intravenous drug users: a systematic review J. Antimicrob. Chemother., November 1, 2007; 60(5): 921 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hoen Epidemiology and antibiotic treatment of infective endocarditis: an update. Heart, November 1, 2006; 92(11): 1694 - 1700. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Falagas, D. K. Matthaiou, and I. A. Bliziotis The role of aminoglycosides in combination with a {beta}-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials J. Antimicrob. Chemother., April 1, 2006; 57(4): 639 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Tsuji and M. J. Rybak Short-Course Gentamicin in Combination with Daptomycin or Vancomycin against Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2735 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Baddour, W. R. Wilson, A. S. Bayer, V. G. Fowler Jr, A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, et al. Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America Circulation, June 14, 2005; 111(23): e394 - e434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Corona, A. P. R. Wilson, M. Grassi, and M. Singer Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy J. Antimicrob. Chemother., October 1, 2004; 54(4): 809 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, I. Benuri-Silbiger, K. Soares-Weiser, and L. Leibovici {beta} lactam monotherapy versus {beta} lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials BMJ, March 20, 2004; 328(7441): 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Task Force Members, D. Horstkotte, F. Follath, E. Gutschik, M. Lengyel, A. Oto, A. Pavie, J. Soler-Soler, G. Thiene, A. von Graevenitz, et al. Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary: The Task Force on Infective Endocarditis of the European Society of Cardiology Eur. Heart J., February 1, 2004; 25(3): 267 - 276. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. DiNubile, D. Koya, K. Ryuichi, M. Haneda, R. Baxter, E. Mylonakis, and S. B. Calderwood Infective Endocarditis N. Engl. J. Med., March 7, 2002; 346(10): 782 - 783. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Graham and F. K. Gould Role of aminoglycosides in the treatment of bacterial endocarditis J. Antimicrob. Chemother., March 1, 2002; 49(3): 437 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ribera, J. M. Miro, E. Cortes, A. Cruceta, J. Merce, F. Marco, A. Planes, J. C. Pare, A. Moreno, I. Ocana, et al. Influence of Human Immunodeficiency Virus 1 Infection and Degree of Immunosuppression in the Clinical Characteristics and Outcome of Infective Endocarditis in Intravenous Drug Users Arch Intern Med, October 12, 1998; 158(18): 2043 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D. Lowy Staphylococcus aureus Infections N. Engl. J. Med., August 20, 1998; 339(8): 520 - 532. [Full Text] [PDF]
|
|
|
|
 |
|
 Single Drug Therapy for Tricuspid Valve Endocarditis Journal Watch Cardiology, January 27, 1997; 1997(127): 9 - 9. [Full Text]
|
|
|
|
 |
|
 SINGLE-DRUG THERAPY FOR RIGHT-SIDED ENDOCARDITIS Journal Watch (General), December 31, 1996; 1996(1231): 2 - 2. [Full Text]
|
|
Article
